• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday

    12/14/22 10:51:33 AM ET
    $BE
    $CVNA
    $CYTK
    $DYN
    Industrial Machinery/Components
    Energy
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary
    Get the next $BE alert in real time by email

    U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session.

    • Avidity Biosciences, Inc. (NASDAQ:RNA) shares jumped 44.3% to $15.84 after the company announced AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever successful targeted delivery of RNA into muscle.
    • Wave Life Sciences Ltd. (NASDAQ:WVE) surged 21.1% to $5.80. SVB Leerink maintained WAVE Life Sciences with a Market Perform and raised the price target from $2 to $7.
    • Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares rose 21.4% to $31.38 after the company announced results from the Phase 1 clinical trial evaluating KT-474 in patients with HS and AD and Sanofi's decision to advance KT-474 into Phase 2 clinical trials.
    • REV Group, Inc. (NYSE:REVG) rose 17.2% to $15.57 as the company reported a fourth-quarter FY22 sales growth of 5.7% year-over-year to $623.6 million, beating the consensus of $595 million.
    • Dyne Therapeutics, Inc. (NYSE:DYN) gained 16.4% to $14.19.
    • Harmonic Inc. (NASDAQ:HLIT) gained 12.9% to $14.86
    • Carvana Co. (NYSE:CVNA) gained 12.8% to $5.45.
    • Harrow Health, Inc. (NASDAQ:HROW) surged 11.9% to $12.43. Harrow Health entered a binding agreement to acquire the exclusive U.S. commercial rights to five FDA‑approved ophthalmic products from Novartis.
    • Bloom Energy Corporation (NYSE:BE) gained 10.3% to $24.26. UBS initiated coverage on Bloom Energy with a Buy rating and announced a price target of $35.
    • Mullen Automotive, Inc. (NASDAQ:MULN) jumped 10% to $0.2354. Mullen Automotive partnered with Loop Global to deploy EV charging solutions, including public DC fast charging network and residential offerings.
    • Oppenheimer Holdings Inc. (NYSE:OPY) gained 9.7% to $44.19. Oppenheimer Holdings announced share repurchase program; authorizes the company to purchase up to 543,000 shares of the company's Class A non-voting common stock.
    • SoFi Technologies, Inc. (NASDAQ:SOFI) rose 9.7% to $4.86. SoFi Technologies CEO Anthony Noto reported purchase of 1,134,065 shares at ab average price of $4.42 per share.
    • Mondee Holdings, Inc. (NASDAQ:MOND) gained 8.8% to $9.50.
    • Plug Power Inc. (NASDAQ:PLUG) rose 8.3% to $15.29. UBS initiated coverage on Plug Power with a Buy rating and announced a price target of $26.
    • Cytokinetics, Incorporated (NASDAQ:CYTK) jumped 7.6% to $41.27. The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 8-3 against the approval of Cytokinetics heart failure drug, omecamtiv mecarbil.

    Check out this: Bitcoin Tops $18,000; GMX, Dogecoin Among Top Losers

    Get the next $BE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BE
    $CVNA
    $CYTK
    $DYN

    CompanyDatePrice TargetRatingAnalyst
    Bloom Energy Corporation
    $BE
    2/24/2026$162.00Neutral
    Citigroup
    SoFi Technologies Inc.
    $SOFI
    2/9/2026$30.00Mkt Perform → Mkt Outperform
    Citizens
    Bloom Energy Corporation
    $BE
    2/6/2026$105.00 → $160.00Hold
    TD Cowen
    Wave Life Sciences Ltd.
    $WVE
    2/5/2026$38.00Buy
    BofA Securities
    SoFi Technologies Inc.
    $SOFI
    2/3/2026$31.00Neutral → Overweight
    Analyst
    SoFi Technologies Inc.
    $SOFI
    2/2/2026$36.00 → $33.00Buy
    Needham
    Bloom Energy Corporation
    $BE
    1/28/2026$153.00Equal Weight
    Barclays
    Kymera Therapeutics Inc.
    $KYMR
    1/28/2026$133.00Overweight
    Barclays
    More analyst ratings

    $BE
    $CVNA
    $CYTK
    $DYN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Soderberg Shawn Marie exercised 20,000 shares at a strike of $30.96, sold $8,091,665 worth of shares (45,244 units at $178.85) and was granted 12,421 shares, increasing direct ownership by 3% to 227,048 units (SEC Form 4)

    4 - Bloom Energy Corp (0001664703) (Issuer)

    2/27/26 9:31:58 PM ET
    $BE
    Industrial Machinery/Components
    Energy

    Officer Francis Chris exercised 33,194 units of Ordinary Shares at a strike of $4.28 and sold $499,593 worth of Ordinary Shares (33,194 units at $15.05) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    2/27/26 9:00:03 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pinkus Gary S sold $207,250 worth of shares (1,250 units at $165.80), decreasing direct ownership by 23% to 4,149 units (SEC Form 4)

    4 - Bloom Energy Corp (0001664703) (Issuer)

    2/27/26 7:55:55 PM ET
    $BE
    Industrial Machinery/Components
    Energy

    $BE
    $CVNA
    $CYTK
    $DYN
    SEC Filings

    View All

    SEC Form S-8 filed by Cytokinetics Incorporated

    S-8 - CYTOKINETICS INC (0001061983) (Filer)

    2/26/26 5:35:35 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Avidity Biosciences Inc.

    8-K - Avidity Biosciences, Inc. (0001599901) (Filer)

    2/26/26 4:58:13 PM ET
    $RNA

    SEC Form 10-K filed by Oppenheimer Holdings Inc.

    10-K - OPPENHEIMER HOLDINGS INC (0000791963) (Filer)

    2/26/26 4:20:45 PM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    $BE
    $CVNA
    $CYTK
    $DYN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Bloom Energy with a new price target

    Citigroup initiated coverage of Bloom Energy with a rating of Neutral and set a new price target of $162.00

    2/24/26 7:46:09 AM ET
    $BE
    Industrial Machinery/Components
    Energy

    SoFi Technologies upgraded by Citizens with a new price target

    Citizens upgraded SoFi Technologies from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    2/9/26 6:58:53 AM ET
    $SOFI
    Finance: Consumer Services
    Finance

    TD Cowen reiterated coverage on Bloom Energy with a new price target

    TD Cowen reiterated coverage of Bloom Energy with a rating of Hold and set a new price target of $160.00 from $105.00 previously

    2/6/26 8:24:09 AM ET
    $BE
    Industrial Machinery/Components
    Energy

    $BE
    $CVNA
    $CYTK
    $DYN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Lavet Robert S bought $105,220 worth of shares (5,000 units at $21.04) (SEC Form 4)

    4 - SoFi Technologies, Inc. (0001818874) (Issuer)

    2/6/26 6:18:51 PM ET
    $SOFI
    Finance: Consumer Services
    Finance

    EVP GBUL Borrow Schuppenhauer Eric bought $99,650 worth of shares (5,000 units at $19.93), increasing direct ownership by 2% to 228,768 units (SEC Form 4)

    4 - SoFi Technologies, Inc. (0001818874) (Issuer)

    2/5/26 5:53:28 PM ET
    $SOFI
    Finance: Consumer Services
    Finance

    Officer Crespo Jose Luis bought $87,282 worth of shares (37,300 units at $2.34), increasing direct ownership by 14% to 307,332 units (SEC Form 4)

    4 - PLUG POWER INC (0001093691) (Issuer)

    12/17/25 9:06:21 PM ET
    $PLUG
    Industrial Machinery/Components
    Energy

    $BE
    $CVNA
    $CYTK
    $DYN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

    Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectivelySAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences, Inc.'s acquisition by Novartis AG. The company is led by Kathl

    2/27/26 9:19:00 AM ET
    $RNA

    Carvana to Present at Upcoming Morgan Stanley Technology, Media & Telecom Conference

    Carvana (NYSE:CVNA), a leading e-commerce platform for buying and selling cars, today announced that Ernie Garcia, Carvana's Founder and Chief Executive Officer, will present to the investor community and host meetings at the upcoming Morgan Stanley Technology, Media & Telecom Conference. Morgan Stanley Technology, Media & Telecom Conference Presentation Date and Time: Monday, March 2, 2026, at 12:20 PM PT* *A webcast of the presentation will be accessible on the Investor Relations section of the Carvana website (https://investors.carvana.com). An archived replay of the webcast will be available following the live presentation. About Carvana Carvana's mission is to change the way pe

    2/27/26 8:00:00 AM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

    SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the company will be presenting one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 8-11, 2026, in Orlando, Florida. 2026 MDA Clinical & Scientific Congress PresentationsOral Presentation: Del-zota Treatment is As

    2/26/26 4:02:00 PM ET
    $RNA

    $BE
    $CVNA
    $CYTK
    $DYN
    Leadership Updates

    Live Leadership Updates

    View All

    Oppenheimer Appoints Vien Le As Managing Director

    Seasoned municipal finance leader joins the firm's Public Finance Investment Banking Group and will be based in Los AngelesNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer), a leading investment bank, wealth manager and a subsidiary of Oppenheimer Holdings Inc. (NYSE:OPY), today announced it has hired Vien Le as Managing Director in the firm's Public Finance Investment Banking Group. Le will be based in Oppenheimer's Los Angeles office and will report to Beth Coolidge, Managing Director and Head of Public Finance. Vien Le joins Oppenheimer with more than two decades of municipal finance experience advising public-sector clients on complex financings across a range

    2/25/26 6:00:00 AM ET
    $OPY
    Investment Bankers/Brokers/Service
    Finance

    Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors

    BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a highly accomplished executive with a strong background in medicine and over 35 years of strategic experience in the biopharmaceutical industry. "Carlo's appointment comes at a pivotal moment for Sparrow as we are looking ahead to pivotal trials of clofutriben for type 2 diabetes and seeking to expand development into other cardiometabolic indications," said Robert Jacks, Sparrow President and Chief Executive Officer. "Carlo is respected globally for

    2/2/26 8:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Plug Power Calls on Stockholders to Act Now and Vote in Favor of Proposals at January 29, 2026 Special Meeting

    SLINGERLANDS, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ:PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, encourages stockholders to vote their shares ahead of the Company's Special Meeting of Stockholders (the "Special Meeting") scheduled for January 29, 2026. The Special Meeting includes proposals that are critical to supporting the Company's ongoing operations, financial flexibility and long-term growth strategy. The Board of Directors urges stockholders of record as of December 12, 2025 (the "Record Date") to vote their shares in favor of all proposals presented at the Special Meeting. This Special Meeting follows the Company's

    1/27/26 2:14:23 PM ET
    $PLUG
    Industrial Machinery/Components
    Energy

    $BE
    $CVNA
    $CYTK
    $DYN
    Financials

    Live finance-specific insights

    View All

    Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass Planning underway to initiate Phase 2a multidose portion of WVE-007 INLIGHT clinical trial for obesity in individuals with higher BMI and comorbidities in 1H 2026, as well as additional trials of WVE-007 as an incretin add-on and as post-incretin maintenance in 2026 Advancing regulatory engagement on potential accelerated approval pathway for WVE-006 (GalNAc-RNA editing) for AATD with feedback anticipated mid-2026; RestorAATion-2 clinical trial fully enrolled through 60

    2/26/26 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 (IRF5) Phase 1 healthy volunteer trial with data expected in 2H26 Dr. Neil Graham, experienced biopharma leader, appointed Chief Development Officer Well-capitalized with $1.6 billion in cash as of December 31, 2025, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral

    2/26/26 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

    MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the fourth quarter and full year of 2025. The company also provided full year 2026 financial guidance. "The fourth qu

    2/24/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BE
    $CVNA
    $CYTK
    $DYN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by REV Group Inc.

    SC 13G/A - REV Group, Inc. (0001687221) (Subject)

    12/6/24 10:11:23 AM ET
    $REVG
    Auto Manufacturing
    Industrials

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care